A Phase I / II, Open - label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with
Advanced Uveal Melanoma
«If we can confirm selumetinib's effectiveness in treating
advanced uveal melanoma in this follow - up trial, it will become the standard therapy for this disease, forming a foundation for new drug combinations that could maximize selumetinib's MEK - inhibitor effect,» he said.
«This is the first study to show that a systemic therapy provides significant clinical benefit in a randomized fashion to
advanced uveal melanoma patients, who have very limited treatment options,» said Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan - Kettering and lead author on the study.
Not exact matches
Though
uveal melanoma is rare — there are only 2,500 cases diagnosed in the United States each year — about half of patients will develop metastatic disease, and survival for patients with
advanced disease has held steady at nine months to a year for decades.
Patients with
uveal melanoma receive surgery to remove the tumor — and in some
advanced cases, the entire eye — as well as radiation therapy or chemotherapy.